` ELEV (Elevation Oncology Inc) vs S&P 500 Comparison - Alpha Spread

ELEV
vs
S&P 500

Over the past 12 months, ELEV has underperformed S&P 500, delivering a return of -55% compared to the S&P 500's +15% growth.

Stocks Performance
ELEV vs S&P 500

Loading
ELEV
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ELEV vs S&P 500

Loading
ELEV
S&P 500
Difference
www.alphaspread.com

Performance By Year
ELEV vs S&P 500

Loading
ELEV
S&P 500
Add Stock

Competitors Performance
Elevation Oncology Inc vs Peers

S&P 500
ELEV
ABBV
AMGN
GILD
VRTX
Add Stock

Elevation Oncology Inc
Glance View

Market Cap
21.6m USD
Industry
Biotechnology

Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.

ELEV Intrinsic Value
1.047 USD
Undervaluation 65%
Intrinsic Value
Price
Back to Top